Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response claim is fully supported by the supplied label excerpts: boxed warning content, Warnings and Precautions monitoring language, and Patient Counseling guidance, with no contradictions.
Category Scores
Accurate Statements
RALDESY has an FDA-labeled warning about suicidal thoughts and behaviors, especially in pediatric and young adult patients.
Boxed Warning excerpt; Warnings and Precautions (5.1); Pediatric Use (8.4)
The label includes monitoring recommendations.
Warnings and Precautions (5.1): monitor all antidepressant-treated patients, especially early and during dosage changes; consider changing/discontinuing in patients with persistent worsening or emergent suicidality
The label includes patient/caregiver counseling to look for suicidality and report symptoms.
Patient Counseling Information (17): advise patients/caregivers to look for emergence of suicidality, especially early and during dosage adjustments, and to report to healthcare provider
Unsupported Statements
Contradictions
Important Omissions
The AI response did not explicitly mention that RALDESY is not approved for pediatric use (though the claim is otherwise correct).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI response accurately reflects boxed warning, monitoring, and counseling language related to suicidality; no unsafe or conflicting details were introduced.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing explicit mention that RALDESY is not approved for pediatric patients.
Suggested Improvement
Include the pediatric non-approval statement (Pediatric Use 8.4 / Boxed Warning) alongside the suicidality monitoring and counseling language.